Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Andre Azevedo Reis Teixeira, Michael Frank Erasmus, Sara D’Angelo, Leslie Naranjo, Fortunato Ferrara, Camila Leal-Lopes, Oliver Durrant, Cecile Galmiche, Aleardo Morelli, Anthony Scott-Tucker & Andrew Raymon Morton Bradbury. (2021) Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. mAbs 13:1.
Read now
Read now
Subramaniyan Manibalan, Kandasamy Thirukumaran, Mathimaran Varshni, Ayyasamy Shobana & Anant Achary. (2020) Report on biopharmaceutical profile of recent biotherapeutics and insilco docking studies on target bindings of known aptamer biotherapeutics. Biotechnology and Genetic Engineering Reviews 36:2, pages 57-80.
Read now
Read now
Minoru Tada, Takuo Suzuki & Akiko Ishii-Watabe. (2018) Development and characterization of an anti-rituximab monoclonal antibody panel. mAbs 10:3, pages 370-379.
Read now
Read now
Simon Krah, Christian Schröter, Stefan Zielonka, Martin Empting, Bernhard Valldorf & Harald Kolmar. (2016) Single-domain antibodies for biomedical applications. Immunopharmacology and Immunotoxicology 38:1, pages 21-28.
Read now
Read now
Renaud Respaud, Laurent Vecellio, Patrice Diot & Nathalie Heuzé-Vourc’h. (2015) Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opinion on Drug Delivery 12:6, pages 1027-1039.
Read now
Read now
Peter J.K. van Meer, Marlous Kooijman, Vera Brinks, Christine C. Gispen-de Wied, Beatriz Silva-Lima, Ellen H.M. Moors & Huub Schellekens. (2013) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. mAbs 5:5, pages 810-816.
Read now
Read now
Geertje J. D. van Mierlo, Nicole H. P. Cnubben, C. Frieke Kuper, Jasja Wolthoorn, Angelique P. van Meeteren-Kreikamp, Machiel M. Nagtegaal, Robert Doornbos, Niels-Christian Ganderup & André H. Penninks. (2013) The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: A demonstrator study using the IL-1 receptor antagonist anakinra. Journal of Immunotoxicology 10:1, pages 96-105.
Read now
Read now
Yen Phung, Wei Gao, Yan-Gao Man, Satoshi Nagata & Mitchell Ho. (2012) High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs 4:5, pages 592-599.
Read now
Read now
John R Adair, Philip W Howard, John A Hartley, David G Williams & Kerry A Chester. (2012) Antibody–drug conjugates – a perfect synergy. Expert Opinion on Biological Therapy 12:9, pages 1191-1206.
Read now
Read now
Trent P. Munro, Stephen M. Mahler, Edwin P. Huang, David Y. Chin & Peter P. Gray. (2011) Bridging the gap. mAbs 3:5, pages 440-452.
Read now
Read now
Articles from other publishers (62)
Marina E. Kirkland, Stephanie Patfield, Anna C. Hughes, Bradley Hernlem & Xiaohua He. (2023) A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy. Antimicrobial Agents and Chemotherapy.
Crossref
Crossref
Maximilian Ruschig, Philip Alexander Heine, Viola Fühner, Kilian Johannes Karl Zilkens, Stephan Steinke, Maren Schubert, Federico Bertoglio & Michael Hust. 2023. Phage Display. Phage Display
15
37
.
Eleana Hatzidaki, Panagiotis Apostolou, Dimitrios Athanasios Ntanovasilis & Ioannis Papasotiriou. (2022) A novel platform for the production of autologous human antibodies. Anti-Cancer Drugs 33:9, pages 903-912.
Crossref
Crossref
Martin A. Rossotti, Kasandra Bélanger, Kevin A. Henry & Jamshid Tanha. (2021) Immunogenicity and humanization of single‐domain antibodies. The FEBS Journal 289:14, pages 4304-4327.
Crossref
Crossref
David Baker, A. Nazli Asardag, Olivia A. Quinn, Alex Efimov & Angray S. Kang. (2021) Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. Human Antibodies 29:4, pages 255-262.
Crossref
Crossref
Dhanusha Sabanathan, Maria E. Lund, Douglas H. Campbell, Bradley J. Walsh & Howard Gurney. (2021) Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Therapeutic Advances in Medical Oncology 13, pages 175883592110229.
Crossref
Crossref
Robert Kernstock, Gizette Sperinde, Deborah Finco, Roslyn Davis & Diana Montgomery. (2020) Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody. The AAPS Journal 22:3.
Crossref
Crossref
Wei-Li Ling, Wai-Heng Lua & Samuel Ken-En Gan. (2020) Sagacity in antibody humanization for therapeutics, diagnostics and research purposes: considerations of antibody elements and their roles. Antibody Therapeutics 3:2, pages 71-79.
Crossref
Crossref
Leslie Naranjo, Fortunato Ferrara, Nicolas Blanchard, Caroline Demangel, Sara D’Angelo, M. Frank Erasmus, Andre A. Teixera & Andrew R.M. Bradbury. (2019) Recombinant Antibodies against Mycolactone. Toxins 11:6, pages 346.
Crossref
Crossref
Nicolas Aubrey & Philippe Billiald. 2019. Human Monoclonal Antibodies. Human Monoclonal Antibodies
231
252
.
Lukas M. Carter, Sophie Poty, Sai Kiran Sharma & Jason S. Lewis. (2018) Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals 61:9, pages 611-635.
Crossref
Crossref
Christine Rothe & Arne Skerra. (2018) Anticalin® Proteins as Therapeutic Agents in Human Diseases. BioDrugs 32:3, pages 233-243.
Crossref
Crossref
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
259
312
.
Jacob Jay, Brinkley Bray, Yaozhi Qi, Eseosaserea Igbinigie, Hao Wu, Jinping Li & Gang Ren. (2018) IgG Antibody 3D Structures and Dynamics. Antibodies 7:2, pages 18.
Crossref
Crossref
Tiina Reinivuori, Pekka Kurki & Paul Chamberlain. (2018) Immunogenicity Assessment of Biosimilars. Pharmaceutical Medicine 32:2, pages 103-121.
Crossref
Crossref
Sebastian Spindeldreher, Bernard Maillère, Evelyne Correia, Maxime Tenon, Anette Karle, Philip Jarvis & Frank Kolbinger. (2018) Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatology and Therapy 8:1, pages 57-68.
Crossref
Crossref
Arnaud Avril, Sebastian Miethe, Michael Hust & Thibaut Pelat. 2018. Phage Display. Phage Display
83
112
.
Jonas Kügler, Florian Tomszak, André Frenzel & Michael Hust. 2018. Phage Display. Phage Display
3
24
.
Sharat Srinivasula, Erin Gabriel, Insook Kim, Paula DeGrange, Alexis St Claire, Candace Mallow, Robert E. Donahue, Chang Paik, H. C. Lane & Michele Di Mascio. (2017) CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. PLOS ONE 12:11, pages e0187912.
Crossref
Crossref
Sven Kronenberg, Elisabeth Husar, Christine Schubert, Christian Freichel, Thomas Emrich, Martin Lechmann, Anna Maria Giusti & Franziska Regenass. (2017) Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies. Regulatory Toxicology and Pharmacology 88, pages 125-137.
Crossref
Crossref
Moustafa Hamze, Sylvain Meunier, Anette Karle, Abdelaziz Gdoura, Amélie Goudet, Natacha Szely, Marc Pallardy, Franck Carbonnel, Sebastian Spindeldreher, Xavier Mariette, Corinne Miceli-Richard & Bernard Maillère. (2017) Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. Frontiers in Immunology 8.
Crossref
Crossref
Eszter Lázár-Molnár, Lisa Scandiuzzi, Indranil Basu, Thomas Quinn, Eliezer Sylvestre, Edith Palmieri, Udupi A. Ramagopal, Stanley G. Nathenson, Chandan Guha & Steven C. Almo. (2017) Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine 17, pages 30-44.
Crossref
Crossref
Tian Yu, Elena Y. Enioutina, Hermine I. Brunner, Alexander A. Vinks & Catherine M. Sherwin. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clinical Pharmacokinetics 56:2, pages 107-125.
Crossref
Crossref
Daniel F.A.R. Dourado & Samuel Coulbourn Flores. (2016) Modeling and fitting protein-protein complexes to predict change of binding energy. Scientific Reports 6:1.
Crossref
Crossref
Rolando Paciello, Richard A. Urbanowicz, Gennaro Riccio, Emanuele Sasso, C. Patrick McClure, Nicola Zambrano, Jonathan K. Ball, Riccardo Cortese, Alfredo Nicosia & Claudia De Lorenzo. (2016) Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. Journal of General Virology 97:1, pages 82-94.
Crossref
Crossref
Benjamin Patrick Werner & Gerhard Winter. (2015) Particle contamination of parenteralia and in-line filtration of proteinaceous drugs. International Journal of Pharmaceutics 496:2, pages 250-267.
Crossref
Crossref
Elizabeth R. Lorden, Howard M. Levinson & Kam W. Leong. (2013) Integration of drug, protein, and gene delivery systems with regenerative medicine. Drug Delivery and Translational Research 5:2, pages 168-186.
Crossref
Crossref
Yi Zhang, Xiaohui Wei, Gaurav Bajaj, Jeffrey S. Barrett, Bernd Meibohm, Amita Joshi & Manish Gupta. (2015) Challenges and considerations for development of therapeutic proteins in pediatric patients. The Journal of Clinical Pharmacology 55:S3, pages S103-S115.
Crossref
Crossref
Cathelijne Kloks, Claudia Berger, Pierre Cortez, Yann Dean, Julia Heinrich, Lisbeth Bjerring Jensen, Vera Koppenburg, Stefan Kostense, Daniel Kramer, Sebastian Spindeldreher & Hishani Kirby. (2015) A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. Journal of Immunological Methods 417, pages 1-9.
Crossref
Crossref
Michaela Gebauer & Arne Skerra. 2015. Biobetters. Biobetters
221
268
.
Roeland Lameris, Renée C.G. de Bruin, Famke L. Schneiders, Paul M.P. van Bergen en Henegouwen, Henk M.W. Verheul, Tanja D. de Gruijl & Hans J. van der Vliet. (2014) Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology 92:3, pages 153-165.
Crossref
Crossref
André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends & Larry Green. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
115
140
.
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf & Juergen Hess. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1463
1500
.
Marjorie A. Shapiro, Patrick G. Swann & M. Stacey Ricci. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1231
1262
.
Melody Sauerborn. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
665
680
.
Daniel R. Getts, William G. Kramer, Alexander C. Wiseman & Stuart M. Flechner. (2014) The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human αβ T Cell Receptor Antibody, in Renal Transplant Patients. Clinical Pharmacokinetics 53:7, pages 649-657.
Crossref
Crossref
S. M. Flechner, S. Mulgoankar, L. B. Melton, T. H. Waid, A. Agarwal, S. D. Miller, F. Fokta, M. T. Getts, T. J. Frederick, J. J. Herrman, J. P. Puisis, L. O'Toole, R. Sung, F. Shihab, A. C. Wiseman & D. R. Getts. (2014) First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. American Journal of Transplantation 14:6, pages 1346-1355.
Crossref
Crossref
B. Hall, C. Kiely, A.M. Tobin & D. McNamara. (2014) HAHA antibodies — Not such a funny story. Journal of Crohn's and Colitis 8:5, pages 439-440.
Crossref
Crossref
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
51
63
.
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
25
47
.
André Frenzel, Jonas Kügler, Sonja Wilke, Thomas Schirrmann & Michael Hust. 2014. Human Monoclonal Antibodies. Human Monoclonal Antibodies
215
243
.
Maliheh Shomali, Angelika Freitag, Julia Engert, Michael Siedler, Zehra Kaymakcalan, Gerhard Winter, John F. Carpenter & Theodore W. Randolph. (2014) Antibody Responses in Mice to Particles Formed from Adsorption of a Murine Monoclonal Antibody onto Glass Microparticles. Journal of Pharmaceutical Sciences 103:1, pages 78-89.
Crossref
Crossref
Aaron Martin, Roland M. Tisch & Daniel R. Getts. (2013) Manipulating T cell-mediated pathology: Targets and functions of monoclonal antibody immunotherapy. Clinical Immunology 148:1, pages 136-147.
Crossref
Crossref
Vera Brinks, Daniel Weinbuch, Matthew Baker, Yann Dean, Philippe Stas, Stefan Kostense, Bonita Rup & Wim Jiskoot. (2013) Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins. Pharmaceutical Research 30:7, pages 1719-1728.
Crossref
Crossref
James G. Barnard, Ken Babcock & John F. Carpenter. (2013) Characterization and Quantitation of Aggregates and Particles in Interferon-β Products: Potential Links Between Product Quality Attributes and Immunogenicity. Journal of Pharmaceutical Sciences 102:3, pages 915-928.
Crossref
Crossref
Lei Zhou, Sarah A. Hoofring, Yu Wu, Thuy Vu, Peiming Ma, Steven J. Swanson, Narendra Chirmule & Marta Starcevic. (2012) Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics. The AAPS Journal 15:1, pages 30-40.
Crossref
Crossref
Fernando Pastor, Mario M Soldevilla, Helena Villanueva, Despina Kolonias, Susana Inoges, Ascensión L de Cerio, Romy Kandzia, Victor Klimyuk, Yuri Gleba, Eli Gilboa & Maurizio Bendandi. (2013) CD28 Aptamers as Powerful Immune Response Modulators. Molecular Therapy - Nucleic Acids 2, pages e98.
Crossref
Crossref
Aakanksha Khandelwal, Haleh Saber, Marjorie A. Shapiro & Hong Zhao. 2013. Antibody-Drug Conjugates and Immunotoxins. Antibody-Drug Conjugates and Immunotoxins
23
38
.
H. Modjtahedi, S. Ali & S. Essapen. (2012) Therapeutic application of monoclonal antibodies in cancer: advances and challenges. British Medical Bulletin 104:1, pages 41-59.
Crossref
Crossref
Patrick J. McEnaney, Christopher G. Parker, Andrew X. Zhang & David A. Spiegel. (2012) Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease. ACS Chemical Biology 7:7, pages 1139-1151.
Crossref
Crossref
Marion G. Ott, Frederik Marmé, Gerhard Moldenhauer, Horst Lindhofer, Michael Hennig, Rolf Spannagl, Mirko M. Essing, Rolf Linke & Diane Seimetz. (2011) Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites. International Journal of Cancer 130:9, pages 2195-2203.
Crossref
Crossref
Simone Giannecchini, Valeria Clausi, Alessandra Vultaggio, Lisa Macera, Fabrizio Maggi, Francesco Martelli, Alberta Azzi, Enrico Maggi & Andrea Matucci. (2012) Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab. Journal of NeuroVirology 18:1, pages 55-61.
Crossref
Crossref
L. Guilleminault, E. Lemarié & N. Heuzé-Vourc’h. (2012) Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer. Journal of Cancer Therapy 03:06, pages 1170-1190.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
377
595
.
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
459
595
.
E-Chiang Lee & Michael Owen. 2012. Antibody Methods and Protocols. Antibody Methods and Protocols
137
148
.
Gary L. Gilliland, Jinquan Luo, Omid Vafa & Juan Carlos Almagro. 2012. Structure-Based Drug Discovery. Structure-Based Drug Discovery
321
349
.
Katherine E. Cornish, Andrew C. Harris, Mark G. LeSage, Dan E. Keyler, Danielle Burroughs, Cathy Earley & Paul R. Pentel. (2011) Combined active and passive immunization against nicotine: Minimizing monoclonal antibody requirements using a target antibody concentration strategy. International Immunopharmacology 11:11, pages 1809-1815.
Crossref
Crossref
Daniel R GettsSushma Shankar, Emily ML Chastain, Aaron Martin, Meghann Teague Getts, Kathryn Wood & Stephen D Miller. (2011) Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 3:7, pages 853-870.
Crossref
Crossref
Dirk Ponsel, Julia Neugebauer, Kathrin Ladetzki-Baehs & Kathrin Tissot. (2011) High Affinity, Developability and Functional Size: The Holy Grail of Combinatorial Antibody Library Generation. Molecules 16:5, pages 3675-3700.
Crossref
Crossref
Patrick G Swann & Marjorie A Shapiro. (2011) Regulatory considerations for development of bioanalytical assays for biotechnology products. Bioanalysis 3:6, pages 597-603.
Crossref
Crossref
Roland E. Kontermann. 2011. Bispecific Antibodies. Bispecific Antibodies
1
28
.